Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer
- 168 Downloads
Treatments for metastatic breast cancer (MBC) are primarily palliative with variable efficacy and outcomes may be influenced by individual differences in drug metabolism. In this study, we examined the association of single nucleotide polymorphisms (SNPs) in genes involved in drug metabolism with progression free survival (PFS) and breast cancer specific survival (BCSS) in 95 patients with MBC that received high dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT). SNPs in the SOD2 (SOD2-01, Val16Ala), MPO (MPO-02, -463 promoter variant) and GSTP1 [GSTP1-01 (Ile105Val), GSTP1-02 (Ala114Val)] genes were examined in DNA isolated from cryopreserved blood products using genotyping assays. Survival was analysed using Cox proportional hazard models and Kaplan–Meier estimates. Patients with the SOD2-01 (TT) genotype had increased risk of disease progression [hazard ratio (HR): 2.52; 95% confidence interval (CI), 1.31–4.85] and breast cancer specific death (HR: 1.92; 95% CI: 1.03–3.57). Risks were increased for patients with both SOD2-01 (TT) and GSTP1-01 (GG or AG) genotypes (HR for disease progression: 2.57, 95% CI: 1.32–5.00 and HR for breast cancer specific death: 2.27; 95% CI: 1.18–4.34). In multivariable analysis, the combined genotype group of SOD2-01 and GSTP1-01 was an independent predictor of PFS and BCSS. HRs progressively increased with increasing number of genotypes associated with worse survival, with p (trend) of 0.005 and 0.006 for PFS and BCSS, respectively. These results suggest that SNPs in genes involved in drug metabolism may influence survival outcome for patients with MBC receiving HDC and ASCT.
KeywordsDrug metabolism Metastatic breast cancer Polymorphisms Survival
We would like to thank the Northern Cancer Research Foundation for their generous support of this research. Also special thanks to Colleen Langdon, Sue Gerard and Jane Vanderklift for their expertise and assistance.
- 9.La TF, Orlando A, Silipigni A, Giacobello T, Pergolizzi S, Aragona M (1997) Increase of oxygen free radicals and their derivatives in chemo- and radiation treated neoplasm patients. Minerva Med 88:121–126Google Scholar
- 17.Woodson K, Tangrea JA, Lehman TA, Modali R, Taylor KM, Snyder K, Taylor PR, Virtamo J, Albanes D (2003) Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control 14:513–518PubMedCrossRefGoogle Scholar
- 21.Dally H, Gassner K, Jager B, Schmezer P, Spiegelhalder B, Edler L, Drings P, Dienemann H, Schulz V, Kayser K et al (2002) Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer 102:530–535PubMedCrossRefGoogle Scholar
- 37.National Cancer Institute (2007) Cancer genome anatomy project. SNP500 cancer database. http://snp500cancer.nci.nih.gov/snplist.cfm
- 38.Brockstedt U, Krajinovic M, Richer C, Mathonnet G, Sinnett D, Pfau W, Labuda D (2002) Analyses of bulky DNA adduct levels in human breast tissue and genetic polymorphisms of cytochromes P450 (CYPs), myeloperoxidase (MPO), quinone oxidoreductase (NQO1), and glutathione S-transferases (GSTs). Mutat Res 516:41–47PubMedGoogle Scholar